3 High Insider Ownership Growth Companies On KRX With Revenue Increases Up To 103%
editorial-team@simplywallst.com (Simply Wall St)
4 min read
The South Korean market has shown resilience, remaining stable over the past week and achieving a 7.2% increase over the past year, with earnings expected to grow by 30% annually. In such an environment, stocks with high insider ownership can be particularly appealing as they often indicate confidence from those who know the company best.
Top 10 Growth Companies With High Insider Ownership In South Korea
Overview: UTI Inc., a company based in South Korea, specializes in the research, development, manufacture, and sale of smartphone camera windows and sensor glasses both domestically and internationally, with a market capitalization of approximately ₩520.53 billion.
Operations: The firm operates primarily in the production and global distribution of smartphone camera windows and sensor glasses.
Insider Ownership: 34.1%
Revenue Growth Forecast: 103.6% p.a.
UTI Inc. in South Korea has been active in private placements, issuing significant amounts of convertible preferred stock and bonds to bolster its financial standing, with transactions closing on May 28 and July 5, 2024. These moves underscore a strategic push to secure growth capital amidst highly volatile share prices. The company's revenue is projected to grow at an impressive rate of 103.6% annually, outpacing the Korean market significantly. Moreover, UTI's return on equity is expected to be very high at 71.4% in three years, reflecting potentially efficient use of shareholder funds despite no substantial insider buying reported over the past three months.
Overview: ALTEOGEN Inc. is a biopharmaceutical company engaged in developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market capitalization of approximately ₩14.50 billion.
Operations: The company generates revenue primarily through the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Insider Ownership: 26.6%
Revenue Growth Forecast: 48.3% p.a.
ALTEOGEN, a South Korean biotech firm, recently received approval from the Ministry of Food and Drug Safety for Tergase®, a high-purity recombinant hyaluronidase. This approval is pivotal as it marks ALTEOGEN's transition to commercial-stage operations. Despite a highly volatile share price in recent months, the company's forecasted revenue growth at 48.3% annually outstrips the national market average significantly. Additionally, earnings are expected to surge by 73.06% annually over the next three years, underpinned by robust non-cash earnings and recent profitability achievements. However, shareholder dilution has occurred over the past year, and there is no recent insider buying activity reported.
Overview: Vuno Inc. is a medical artificial intelligence (AI) solution development company with a market cap of approximately ₩457.62 billion.
Operations: The company generates revenue primarily from its artificial intelligence medical software production, totaling approximately ₩17.04 billion.
Insider Ownership: 19.5%
Revenue Growth Forecast: 41.4% p.a.
Vuno, a South Korean company, is poised for significant growth with expected revenue increases of 41.4% annually, surpassing the local market's 10.8%. It's projected to turn profitable within three years—a rate above the market average. Despite this promising outlook, challenges include a highly volatile share price and recent shareholder dilution. Additionally, its Return on Equity is anticipated to reach a very high level (117%) in three years, reflecting potentially efficient use of shareholders' equity.
Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include KOSDAQ:A179900KOSDAQ:A196170KOSDAQ:A338220 and
